SEC Filing Summary: Ventrus Biosciences, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Ventrus Biosciences, Inc. (not Assembly Biosciences, Inc.) on January 7, 2011. The report covers events occurring on the same date regarding the company's initial public offering (IPO).
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the exercise of an over-allotment option:
- Additional Shares Issued: 435,000 shares
- Price Per Share: $6.00
- Total Proceeds from Over-Allotment: $2,610,000 (calculated)
Material Changes
The material event reported is the full exercise of the underwriters' over-allotment option to purchase an additional 435,000 shares of the company's common stock at the IPO price of $6.00 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the announcement of the share issuance.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-IPO including the 435,000 additional shares.
- Confirm the total gross proceeds raised from the IPO and the over-allotment exercise.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds.
- Note the discrepancy between the requested company name (Assembly Biosciences) and the filing registrant (Ventrus Biosciences).